ClinicalTrials.gg
Active, not recruitingNCT05000281Updated Nov 16, 2026

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures

A Phase 3 interventional study of 600 mg Ibuprofen in Tibia Fracture and Pain, sponsored by Major Extremity Trauma Research Consortium. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Major Extremity Trauma Research Consortium · Phase 3, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Tibial Fractures with a site in United States — 15 open to participants now, 18 under way, 3 of them phase 3. Tibial Fractures · United States.

Planned enrollment
3rd of 38
700 · median 53
Started
2021
with 4 others
Phase 3
4 of 50
2 open now
Primary completion
2026-11
later than 5 of 17 live
Registered
33rd of 50
by date
Lead sponsor
3 of 50
Major Extremity Trauma Research Consortium

Among the 50 studies in Tibial Fractures with a site in United States, this one is the 3rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2021, is one of 4 in phase 3, reaches primary completion later than 5 of the 17 other live ones, and was the 33rd registered.

Tibial Fractures

136 studies on the registry are indexed under Tibial Fractures; 38 are open to participants now.

Browse Tibial Fractures studies →

Open to participants now

15 of the 50 studies in Tibial Fractures with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Tibial Fractures studies recruiting now, 13 (48%) set no upper age limit and 7 (26%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Tibial Fractures with a site in United States, or all of them as a file.
02

Study summary

The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial evaluating the efficacy of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.

Read the detailed description

The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial. Patients with diaphyseal tibia fractures treated with intramedullary (IM) nail will be randomized into two treatment arms. The control arm will receive standard pain management with no NSAIDs. The treatment arm will receive standard pain management plus up to six weeks of NSAIDs (3 weeks of prescribed medication followed by 3 weeks of medication PRN).

The hypothesis is that pain management using up to 6 weeks of NSAIDs will result in improved pain control and lower opioid consumption but demonstrate non-inferior levels of complications compared to standard of care pain management. The aim of the study is to:

Specific Aim: Evaluate the effect of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.

Primary Hypothesis: When compared to patients who received standard of care pain management, patients treated with up to 6 weeks of NSAIDs will have noninferior rates of surgery for to promote union at one year.

Secondary Hypotheses: When compared to patients who received standard of care pain management without NSAIDs, patients treated with up to 6 weeks of NSAIDs will benefit from (1) reduced opioid utilization; (2) reduced levels of persistent pain; (3) reduced pain interference; (4) improved functional outcomes; (5) noninferior rates of analgesic treatment related side effects; and (6) noninferior rates of radiographic union.

Study design: At time of IM nailing surgery for acute diaphyseal tibia fracture, patients will be randomized to treatment or control group. Treatment patients will receive a standard of care pain regimen and oral ibuprofen 600 mg three times a day (tid) for up to six weeks (3 weeks of prescribed medication followed by 3 weeks of medication PRN). Control patients will receive a standard of care pain regimen prescribed by the treating physician and may not use NSAIDs. Patient medication adherence will be calculated separately on an inpatient and outpatient basis, for a summary.

Follow-Up: Clinical, functional, and radiographic follow-up will be conducted at typical standard of care intervals of 2-3 weeks, 6 weeks, 3 months, 6 months, and one year.

Sample size: At least 650, up to 700

Number of study sites: 14 sites

Study population: The study population will consist of a relatively homogeneous group of orthopaedic trauma patients ages 18-80 with open (grade I, II or IIIa) or closed diaphyseal tibia fractures.

03

Conditions studied

  • Tibia Fracture
  • Pain

Keywords

  • NSAID
  • Nonsteroidal Anti-Inflammatory Drug
  • Opioid Utilization
  • Nonunion Surgery
  • Fracture Healing
  • Orthopaedic trauma
  • Pain Management
  • IM Nail Fixation
  • Tibia Fracture
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients with open (Grade I, II, of IIIa) or closed tibia fractures treated with a nail.
  • Patients 18-80 years old inclusive.
  • Patients able to be followed at a Major Extremity Trauma \& Rehabilitation (METRC) facility for at least 12 months following injury

Exclusion criteria

Exclusion Criteria:

  • Patient unable to provide
  • Patients who are current - intravenous drug user.
  • Patients with a history of allergy to the study drugs.
  • Patients unable to swallow oral medications or without functioning GI tract.
  • Patients with a history of gastrointestinal bleeds or gastric perforation.
  • Patients with a history of stroke or heart attack.
  • Patients requiring an aspirin or NSAID regimen except for low dose aspirin, 81mg.
  • Patients with any bleeding disorders.
  • Patients with severe renal failure [ (GFR):\<30]. Patients with moderate renal failure [GFR: 30-59] may participate in the study at a modified dose.
  • Patients undergoing daily treatment with systemic before surgery.
  • Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.
  • Patients with a Glasgow Coma Scale (GCS) \<15 at discharge.
  • Patients with a closed head injury that precludes NSAIDS.
  • Patients who are pregnant or lactating at time of screening
  • Patients with a bone graft procedure planned for a future date at the time of initial definitive fixation surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Active comparator
    Standard of Care Pain Management with NSAIDs

    Arm Description: Treatment patients will receive oral ibuprofen 600 mg three times a day (tid) for up to six weeks. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs.

    Drug: 600 mg Ibuprofen

  • No intervention
    Standard of Care Pain Management Without NSAIDS

    Control patients will receive standard of care pain medication regimen and may not use NSAIDs. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs.

Interventions

  • DrugIbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment patients will receive oral ibuprofen 600 mg three times a day (tid) for up to six weeks. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs.

    Also known as: Advil, Motrin

06

What researchers measure

Primary outcomes

  1. The primary outcome will be based on evidence of a secondary surgery to promote union after 3 months and up to 12 months post definitive fixation surgery

    Nonunion will be assessed by the presence of a secondary surgery to promote union after 3 months and up to 12 months post definitive fixation surgery. Surgery operative notes and radiographs of each case will be independently reviewed by members of the METRC Central Adjudication Committee . The METRC Central Adjudication Committee will convene to discuss the cases for which there is disagreement regarding nonunion assessment, with final status determined by agreement of at least 2 reviewers.

    Time frame: Between 3 months and 12 months after definitive fixation surgery

Secondary outcomes

  1. Pain as assessed by the Brief Pain Inventory (BPI)

    The Brief Pain Inventory (BPI) is a widely used, 15-item measure of pain intensity and interference with daily life and will be assessed at baseline, 3, 6, and 12 months post definitive fixation surgery. It has been extensively validated in both English and Spanish, and also includes questions about pain treatments and the effectiveness of these treatments.46 The BPI pain intensity domain is compatible with the IMMPACT guidelines for assessing pain in clinical trials and the FDA Guidance for Industry on the use of Patient-Reported Outcome Measures.

    Time frame: 3, 6, 12, months

  2. Pain interference as assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference

    One of the domains assessed by The Patient Report Outcomes Measurement Information System (PROMIS) Computer Adaptive Test (CAT) includes Pain Interference. CATs present an advantage over traditional measures in that they target only the most relevant items to each patient and can thus be used to obtain precise measurements with 4-6 items, making assessment across multiple domains feasible. CATs can also extend the ceiling and floor of individual domains, potentially enhancing responsiveness.

    Time frame: 3, 6, 12, months

  3. Physical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS)

    Self -Reported Measures of Physical and Psychosocial Function will be assessed using the Patient Report Outcomes Measurement Information System (PROMIS) Computer Adaptive Test (CAT) item banks, a product of the NIH Roadmap for Medical Research. CATs present an advantage over traditional measures in that they target only the most relevant items to each patient and can thus be used to obtain precise measurements with 4-6 items, making assessment across multiple domains feasible.

    Time frame: 3, 6, 12, months

  4. Radiographic union as assessed by the modified Radiographic Union Scale in Tibial Fractures (mRUST)

    Radiographic union will be based on the modified RUST(mRUST) score assessed between 3 months and 12 months after definitive fixation surgery. The four cortices of the tibia fracture will be assessed and given a score from 1-4, 1=not healed, 4=healed. The mRUST score is the sum of the 4 cortical scores (4-16) and a score of 13 or greater is considered a healed fracture. Radiographic examinations at 3, 6 and 12 months by an adjudication committee comprised of METRC investigators will be evaluated based on AP and lateral x-rays.

    Time frame: Between 3 months and 12 months after definitive fixation surgery

  5. Adverse Effects and Complications

    Adverse Effects and Complications: Adverse effects and complications of ibuprofen include, in addition to nonunion, wound closure complications, bleeding complications, as well as pain treatment related adverse effects. Adverse effects include nausea, vomiting, dizziness, headaches, renal impairment, platelet inhibition and angioedema.

    Time frame: Enrollment -12 months

07

Study locations

1 site
08

References and documents

Publications

  • Castillo RC, Raja SN, Frey KP, Vallier HA, Tornetta P 3rd, Jaeblon T, Goff BJ, Gottschalk A, Scharfstein DO, O'Toole RV; METRC. Improving Pain Management and Long-Term Outcomes Following High-Energy Orthopaedic Trauma (Pain Study). J Orthop Trauma. 2017 Apr;31 Suppl 1:S71-S77. doi: 10.1097/BOT.0000000000000793. PubMed 28323806 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2021 (actual). Primary completion is estimated for Nov 2026, 62 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Sep 2024 → Nov 2026 and completion Dec 2024 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 11, 2021
StartActual
Sep 14, 2021
Primary completionEst.
Nov 30, 2026was Sep 2024
CompletionEst.
Jan 1, 2027was Dec 2024
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Nov 16, 2026
Primary completion
Sep 2024→Nov 30, 2026
Nov 16, 2026
Study completion
Dec 2024→Jan 1, 2027
Nov 16, 2026
Enrollment
1000→700
Nov 16, 2026
Interventions
Changed Ibuprofen→600 mg Ibuprofen. Arm changed NSAID→Standard of Care Pain Management with NSAIDs. Arms added: Standard of Care Pain Management Without NSAIDS; arms removed: No NSAIDs
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Numbers of participants with nonunion (secondary surgery to promote union)Now The primary outcome will be based on evidence of a secondary surgery to promote union after 3 months and up to 12 months post definitive fixation surgeryTime frame: Between 3 months and 12 months after definitive fixation surgery
Nov 16, 2026
Secondary outcomes
3 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • AddedAdverse Effects and ComplicationsTime frame: Enrollment -12 months
  • Time framePain as assessed by the Brief Pain Inventory (BPI)Baseline, 3, 6, 12, months → 3, 6, 12, months
  • Time framePain interference as assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Pain InterferenceBaseline, 3, 6, 12, months → 3, 6, 12, months
  • Time framePhysical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS)Baseline, 3, 6, 12, months → 3, 6, 12, months
  • DescriptionPhysical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS): how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Status unknown→Active, not recruiting
    Primary completion Sep 2024→Nov 30, 2026
    Study completion Dec 2024→Jan 1, 2027
    Enrollment 1000→700
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Numbers of participants with nonunion (secondary surgery to promote union)Now The primary outcome will be based on evidence of a secondary surgery to promote union after 3 months and up to 12 months post definitive fixation surgeryTime frame: Between 3 months and 12 months after definitive fixation surgery
    Secondary outcomes 3 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • AddedAdverse Effects and ComplicationsTime frame: Enrollment -12 months
    • Time framePain as assessed by the Brief Pain Inventory (BPI)Baseline, 3, 6, 12, months → 3, 6, 12, months
    • Time framePain interference as assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Pain InterferenceBaseline, 3, 6, 12, months → 3, 6, 12, months
    • Time framePhysical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS)Baseline, 3, 6, 12, months → 3, 6, 12, months
    • DescriptionPhysical and Psychosocial functioning as assessed by Patient Report Outcomes Measurement Information System (PROMIS): how it is measured was reworded
    Interventions Changed Ibuprofen→600 mg Ibuprofen. Arm changed NSAID→Standard of Care Pain Management with NSAIDs. Arms added: Standard of Care Pain Management Without NSAIDS; arms removed: No NSAIDs
    + 10 other changes: identifiers, verification date, responsible party, description, conditions, design details, contact details, site details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05000281
Lead sponsor
Major Extremity Trauma Research Consortium
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Aug 11, 2021
Start date
Sep 14, 2021
Primary completion
Nov 30, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Thomas Higgins, MD
principal investigator · University of Utah
Renan Castillo, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion